Financial Performance - The company's operating revenue for the third quarter was RMB 149,723,992.40, representing a 92.93% increase compared to the same period last year[4]. - The net profit attributable to shareholders for the third quarter was a loss of RMB 143,600,577.66, a decrease of 70.49% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 186,431,076.05, down 64.54% from the previous year[4]. - The overall operating revenue for the year-to-date period was RMB 175,631,799.90, reflecting a decrease of 75.17% compared to the same period last year due to a significant drop in COVID-19 vaccine sales[4]. - The company experienced a net loss attributable to shareholders of RMB 985,029,654.47 for the year-to-date period, an increase of 107.63% compared to the previous year[4]. - The net loss for the first three quarters of 2023 was ¥1,454,919,925.84, compared to a net loss of ¥488,682,218.46 in the same period of 2022, representing an increase in losses of about 197.5%[24]. Research and Development - Research and development expenses totaled RMB 140,476,879.33 for the quarter, a decrease of 38.80% compared to the same period last year[4]. - Research and development expenses decreased by 38.80% in the current reporting period, mainly due to a shift in focus away from COVID-19 vaccine-related R&D[10]. - The proportion of R&D expenses to operating income decreased by 201.94 percentage points in the current reporting period[10]. - The proportion of R&D expenses to operating income increased by 194.71 percentage points year-to-date, indicating a larger decline in operating income compared to R&D expenses[10]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 9,610,642,425.30, a decrease of 19.34% from the end of the previous year[5]. - The equity attributable to shareholders at the end of the reporting period was RMB 5,770,626,650.09, down 16.94% year-on-year[5]. - As of September 30, 2023, total assets amounted to ¥9,610,642,425.30, a decrease from ¥11,468,958,286.71 as of December 31, 2022, representing a decline of approximately 16.1%[18]. - Total liabilities decreased to ¥3,812,394,223.51 from ¥4,223,356,561.52, reflecting a reduction of about 9.7%[20]. - The total equity attributable to shareholders decreased to ¥5,770,626,650.09 from ¥6,748,089,902.12, a decline of about 14.5%[21]. Earnings Per Share - The basic earnings per share for the third quarter was a loss of RMB 0.58, a decrease of 70.46% compared to the same period last year[4]. - Basic and diluted earnings per share for the first three quarters of 2023 are both (3.99) CNY, up from (1.92) CNY in the same period of 2022, reflecting improved profitability[26]. Cash Flow - The net cash flow from operating activities decreased by 46.24% year-to-date, primarily due to reduced cash payments for raw materials[9]. - Cash flow from operating activities for the first three quarters of 2023 shows a net outflow of (748,974,021.75) CNY, an improvement from a net outflow of (1,393,277,778.30) CNY in the same period of 2022[28]. - Cash inflow from investment activities for the first three quarters of 2023 is 6,640,825,701.63 CNY, down from 9,360,944,181.35 CNY in the same period of 2022[29]. - Cash flow from financing activities for the first three quarters of 2023 shows a net outflow of (131,319,499.65) CNY, compared to a net inflow of 628,604,712.22 CNY in the same period of 2022[29]. - The net increase in cash and cash equivalents for the first three quarters of 2023 is (1,040,273,125.42) CNY, with an ending balance of 2,350,994,729.85 CNY[30]. Sales Performance - The company reported a significant increase in sales revenue from its meningitis vaccine products, contributing to the rise in operating revenue for the quarter[8]. - The revenue from the combined meningococcal vaccine reached approximately 371.15 million RMB in the first three quarters of 2023, a year-on-year increase of approximately 476.47%[14]. - The total sales revenue for the group was approximately 414.39 million RMB, with a revenue reduction of approximately 238.76 million RMB due to returns[14].

Financial Performance - Revenue for the first half of 2023 was RMB 21,086 thousand, a decrease of 96.7% compared to RMB 629,790 thousand in the same period of 2022[7]. - Operating loss increased to RMB 1,342,432 thousand, compared to a loss of RMB 164,800 thousand in the first half of 2022, representing a 714.6% increase[7]. - Total comprehensive loss for the period was RMB 1,282,024 thousand, a significant decline from a profit of RMB 16,043 thousand in the same period last year, marking an 8,091.2% change[7]. - Basic and diluted loss per share was RMB (3.4098), compared to earnings of RMB 0.0495 per share in the first half of 2022, reflecting a 6,988.5% decrease[7]. - The company reported a net loss of RMB 841,429,000, compared to a profit of RMB 12,238,000 for the same period in 2022[109]. - The gross loss for the period was RMB (776,487) thousand, compared to a gross profit of RMB 316,173 thousand in the prior year[106]. - The company reported a loss before tax of RMB (1,283,335,000), compared to a loss of RMB (41,555,000) for the same period in 2022, indicating a significant increase in losses[143]. - The basic loss per share for the six months ended June 30, 2023, was RMB (3.41), compared to a profit of RMB 0.05 per share for the same period in 2022, reflecting a substantial decline in profitability[146]. - The company did not declare or pay any dividends for the six months ended June 30, 2023, following a total dividend payout of RMB 197,560,000 for the previous year[148]. Assets and Liabilities - Total assets decreased by 13.7% to RMB 9,897,272 thousand as of June 30, 2023, down from RMB 11,468,960 thousand at the end of 2022[8]. - Total equity decreased by 17.6% to RMB 5,969,259 thousand, compared to RMB 7,245,602 thousand at the end of 2022[8]. - The company's total liabilities decreased by 14.3% from approximately RMB 791.9 million as of December 31, 2022, to approximately RMB 678.8 million as of June 30, 2023, primarily due to a decrease in wages and benefits payable of approximately RMB 77.9 million[62]. - The company's total liabilities decreased from RMB 63,095,000 as of January 1, 2022, to RMB 56,936,000 as of June 30, 2023[160]. - The company’s total liabilities increased, with borrowings repaid amounting to RMB 1,229,022,000 during the period[110]. - The company’s total equity attributable to owners decreased to RMB 5,912,489,000 as of June 30, 2023, from RMB 6,748,090,000 at the beginning of the year[109]. Research and Development - The company has a diverse vaccine product line, including innovative vaccines targeting unmet medical needs globally[12]. - Ongoing research includes mRNA COVID-19 vaccines and tuberculosis booster vaccines, indicating a focus on advanced vaccine development[12]. - The company aims to expand its market presence with a broad portfolio of vaccines addressing over ten disease areas[12]. - The company has initiated Phase III clinical trials for the potential best-in-class PCV13i vaccine, with completion of site work in 2022 and plans to start new drug application procedures in the second half of 2023[20]. - The innovative PBPV vaccine, which targets over 90 serotypes of pneumonia, has entered Phase Ib clinical trials as of March 2023, with all subjects enrolled[21]. - The infant DTcP vaccine has officially started Phase III clinical trials in August 2023, with the first subject enrolled, aiming for new drug application procedures in 2025[22]. - The company is developing a Tdcp vaccine for adolescents and adults, which has received clinical trial approval from the National Medical Products Administration in June 2023, with Phase I trials expected to start in the second half of 2023[24]. - The company has obtained exclusive global licensing from McMaster University for the Ad5Ag85A tuberculosis vaccine, which has shown good safety and tolerance in Phase Ia trials, with plans to initiate new drug clinical trial applications in Indonesia in 2024[25]. - The recombinant shingles vaccine developed by the company has received a no-objection letter for clinical trials from Health Canada in July 2023, with both intramuscular injection and aerosol inhalation methods approved for trials[26]. - The company’s tetanus vaccine, developed using animal-free culture media, has received clinical trial approval for individuals aged 18 and above, with Phase I trials expected to start in 2023[27]. - The mRNA COVID-19 vaccine is still in clinical trials, with future development plans contingent on the tracking of variant strains and national immunization strategies[28]. Market and Sales - The revenue from the company's meningococcal vaccine products reached approximately RMB 222.6 million, up from RMB 10.6 million in the same period of 2022, driven by ongoing marketing and commercialization efforts[36]. - The company plans to continue the commercialization of its vaccines and strengthen its marketing efforts to enhance public awareness of vaccination[35]. - The company has established a comprehensive commercial operation center and aims to expand its marketing network while controlling sales expenses[35]. - The company will continue to explore global collaborations and acquisitions related to vaccines and bioproducts to enhance its international market competitiveness[35]. Cash Flow and Investments - The total cash used in operating activities was RMB 753,907,000, an improvement from RMB 1,215,901,000 in the previous year[110]. - The company invested RMB 2,815,000,000 in equity and fund investments during the period, a decrease from RMB 6,681,912,000 in the previous year[110]. - The company plans to invest approximately RMB 2,244.7 million in the CanSino Innovative Vaccine Industrial Park project to enhance manufacturing capabilities, with RMB 376.2 million already invested[68]. - The company has established foreign exchange risk hedging agreements with several commercial banks to mitigate foreign exchange risks[71]. - The company has repurchased 683,748 A-shares at a total cost of approximately RMB 150.2 million, which includes transaction costs of RMB 152,000[99]. Shareholder Information - As of June 30, 2023, Dr. Yu holds 34,598,400 H shares (13.98%) and 42,579,625 A shares (17.21%), representing approximately 26.08% and 37.10% of the respective classes of shares[83]. - The Capital Group Companies, Inc. holds 16,747,482 H shares (6.77%), accounting for approximately 12.62% of the total equity[88]. - JPMorgan Chase & Co. holds 7,335,430 H shares (2.96%) and has additional positions in 4,838,049 shares (1.96%) and 1,730,219 shares (0.70)[88]. - Qiming Corporate holds 7,516,538 H shares (3.04%), representing approximately 5.67% of the relevant class of shares[89]. Compliance and Governance - The audit committee reviewed the unaudited interim results for the six months ended June 30, 2023, and found them compliant with applicable accounting standards[80]. - The company’s independent auditor, Deloitte, conducted a review of the interim financial information in accordance with the relevant standards[81]. - The company has no other disclosures regarding the interests or short positions of directors or senior management in the company’s shares as of June 30, 2023[86]. - The company’s major shareholders, excluding directors and senior management, have disclosed their interests in the company’s shares as required by the Securities and Futures Ordinance[87]. - The company’s board consists of three independent non-executive directors overseeing financial reporting and risk management systems[80].

Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a 15% increase compared to the same period last year[1]. - The company's revenue for the first half of 2023 was CNY 25,907,807.50, a decrease of 95.89% compared to CNY 629,790,353.02 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was a loss of CNY 841,429,076.81, compared to a profit of CNY 12,238,427.20 in the previous year, representing a decrease of 6,975.30%[19]. - The net cash flow from operating activities was a negative CNY 737,403,150.66, a 39.23% improvement from a negative CNY 1,213,518,523.05 in the same period last year[19]. - The total assets decreased by 13.70% to CNY 9,897,271,179.30 from CNY 11,468,958,286.71 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 12.38% to CNY 5,912,488,550.94 from CNY 6,748,089,902.12 at the end of the previous year[19]. - The basic earnings per share for the first half of 2023 was CNY -3.41, a decrease of 6,920.00% compared to CNY 0.05 in the same period last year[20]. - The diluted earnings per share also stood at CNY -3.41, reflecting the same significant decline as the basic earnings per share[20]. - The company reported a net profit after deducting non-recurring gains and losses of CNY -892,960,573.30, compared to CNY -56,768,490.38 in the previous year, marking an increase of 1,472.99%[19]. Research and Development - Research and development expenses increased by 25% to RMB 300 million, focusing on new vaccine technologies[1]. - The R&D expenditure as a percentage of revenue was 1,310.33%, an increase of 1,258.53 percentage points from 51.80% in the previous year[20]. - The company has developed five major technology platforms for vaccine research, showcasing advanced capabilities in viral vector vaccines, synthetic vaccines, protein structure design, mRNA technology, and formulation techniques[51][52][53][54][55]. - The company is focused on developing vaccines for significant clinical needs, including meningococcal, COVID-19, pertussis, pneumonia, tuberculosis, and shingles[25]. - The company has established a comprehensive vaccine R&D platform, securing over 30 invention patents and publishing in renowned medical journals[66]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[1]. - A strategic partnership was announced with a leading pharmaceutical company to enhance distribution channels, expected to increase sales by 15%[1]. - The company is exploring potential acquisitions to strengthen its product portfolio, with a budget of RMB 500 million allocated for this purpose[1]. - The company is actively monitoring the evolution of COVID-19 variants to inform its vaccine development strategy[29]. - The company has initiated international expansion, establishing vaccine production bases in countries like Pakistan and Mexico for localized COVID-19 vaccine production[70]. Regulatory and Compliance - The implementation of the Vaccine Administration Law in China has introduced stricter regulations across various stages of vaccine production and distribution, promoting industry consolidation and scale efficiency[47]. - The company has not reported any major asset or equity sales during the reporting period[113]. - The company has committed to transparency in reporting any changes in shareholding by its directors and senior management[138]. - The company has established a framework for accountability in case of any violations of the commitments made regarding shareholding[138]. Environmental Initiatives - The company invested 3.9846 million CNY in environmental protection during the reporting period[126]. - The company reduced carbon emissions by 3,478.6 tons through various measures, including energy audits and upgrading equipment for energy efficiency[131]. - The company has established an environmental management system and has not faced any administrative penalties for environmental violations during the reporting period[129]. - The company is focusing on low-carbon production and green energy-saving development concepts, enhancing corporate culture around green practices[131]. Shareholder and Governance - The company has approved a three-year dividend return plan for shareholders from 2023 to 2025[117]. - The company has initiated an employee stock ownership plan for 2023, which was approved in the recent shareholder meeting[117]. - The company has authorized the board to repurchase H shares and A shares, indicating a strategy to enhance shareholder value[118]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments[173]. Financial Health and Risks - The company faces risks related to core competitiveness, operational challenges, and financial risks due to the competitive nature of the vaccine industry and potential market changes[90][91][92]. - The company recorded an asset impairment loss of ¥711,717,561.04, an increase of 615,101,003.49 compared to the same period last year, primarily due to impairment provisions for inventory and long-term assets[102]. - The total amount of guarantees provided by the company during the reporting period (excluding guarantees to subsidiaries) is 790,000,000.00 RMB[187]. - The total guarantee balance at the end of the reporting period (excluding guarantees to subsidiaries) is 392,115,088.37 RMB, which accounts for 6.57% of the company's net assets[187].

Financial Performance - For the six months ended June 30, 2023, the revenue was RMB 21,086 thousand, a decrease of 96.7% compared to RMB 629,790 thousand in the same period of 2022[8]. - The operating loss for the same period was RMB 1,342,432 thousand, an increase of 714.6% from RMB 164,800 thousand in the previous year[8]. - The loss before income tax was RMB 1,283,335 thousand, representing a significant increase of 2,988.3% compared to RMB 41,555 thousand in 2022[8]. - Total comprehensive loss for the period was RMB 1,282,024 thousand, a decline of 8,091.2% from a profit of RMB 16,043 thousand in the prior year[8]. - Basic and diluted loss per share was RMB (3.4098), a decrease of 6,988.5% from earnings of RMB 0.0495 per share in 2022[8]. - The company recorded a revenue of approximately RMB 21.1 million for the six months ended June 30, 2023, a significant decrease from RMB 629.8 million for the same period in 2022, primarily due to reduced demand for COVID-19 vaccine products and a provision for expected returns of RMB 237.1 million[40]. - The company reported a net loss of RMB 841,429 thousand for the six months ended June 30, 2023, compared to a net loss of RMB 1,282,024 thousand for the same period in 2022, indicating an improvement of approximately 34.4%[121]. Assets and Liabilities - As of June 30, 2023, total assets were RMB 9,897,272 thousand, down 13.7% from RMB 11,468,960 thousand at the end of 2022[10]. - Total equity decreased by 17.6% to RMB 5,969,259 thousand from RMB 7,245,602 thousand at the end of 2022[10]. - Non-current assets increased by 6.2% to RMB 3,969,248 thousand from RMB 3,738,775 thousand at the end of 2022[10]. - The company’s total liabilities decreased to RMB 3,928,013 thousand as of June 30, 2023, from RMB 4,223,358 thousand as of December 31, 2022, a decrease of approximately 7.0%[119]. - The company’s borrowings decreased to RMB 2,204,910 thousand as of June 30, 2023, from RMB 2,453,585 thousand as of December 31, 2022, a reduction of about 10.1%[119]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[11]. - The company has a broad vaccine pipeline targeting over ten disease areas, with five commercialized products currently[17]. - The company aims to address unmet medical needs globally with innovative vaccines, including mRNA COVID-19 vaccines and other candidates in clinical development[17]. - The company has initiated Phase III clinical trials for the DTcP vaccine for infants as of August 2023, with expectations to start the new drug application process in 2025[24]. - The company has launched Phase I clinical trials for the Tdcp vaccine for adolescents and adults, with approval received in June 2023, targeting populations aged 6 and above[26]. Market and Product Development - The company has received approval for the commercialization of the meningococcal vaccines Meinaixi® and Manhaixin®, with Meinaixi® being the best bivalent meningococcal vaccine in China and Manhaixin® being the first MCV4 vaccine approved in the country[17]. - The recombinant COVID-19 vaccine Kweisha® has received emergency use authorization overseas and conditional marketing approval in China as of June 30, 2023[20]. - Kweisha® has been widely administered as a booster vaccine in China since September 2022, with emergency use authorizations granted in Morocco and Indonesia[20]. - The company has established a comprehensive commercial operation center to implement marketing strategies for Manhaixin®[17]. - The company is actively expanding its marketing system and has identified key vaccination points and opinion leaders across China to promote its products, including the meningococcal vaccine[37]. Financial Position and Cash Flow - Cash and bank balances decreased by 29.6% from approximately RMB 3,394.8 million as of December 31, 2022, to approximately RMB 2,389.2 million as of June 30, 2023, attributed to reduced sales revenue and cash outflows from operating activities[69]. - Operating cash flow for the six months ended June 30, 2023, was a net outflow of RMB 753,907 thousand, an improvement from a net outflow of RMB 1,215,901 thousand in the same period of 2022[123]. - The company reported financial income of RMB 59,097 thousand for the period, down from RMB 123,245 thousand in the previous year, indicating a decrease of about 52.00%[116]. Corporate Governance - The company has adopted the corporate governance code and believes it has complied with all applicable provisions during the reporting period, except for the separation of the roles of Chairman and CEO, which are both held by Dr. Yu[80]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the interim financial results for the six months ending June 30, 2023, and found them to comply with applicable accounting standards[84]. - The independent auditor, Deloitte, reviewed the interim financial information in accordance with the Hong Kong Institute of Certified Public Accountants' standards[85]. - The company will continue to review the effectiveness of its corporate governance structure, including the potential separation of the roles of Chairman and CEO[80]. Shareholder Information - As of June 30, 2023, Dr. Yu holds 34,598,400 H shares (13.98%) and 42,579,625 A shares (17.21%), representing approximately 26.08% and 37.10% of the respective classes of shares[89]. - The company did not recommend the payment of an interim dividend for the reporting period, consistent with the previous year[86]. - The company has repurchased 683,748 A-shares at a total cost of approximately RMB 150.2 million, with 277,650 shares allocated for the employee stock ownership plan as of June 30, 2023[108]. Impairment and Provisions - The group recognized an impairment loss of approximately RMB 325,401,000 for property, plant, and equipment as of June 30, 2023[142]. - The company recognized impairment losses of RMB 332,846,000 for inventory and RMB 325,401,000 for property, plant, and equipment related to COVID-19 vaccine products[127]. - The company adjusted the estimated future sales returns for sold products, resulting in a revenue adjustment of RMB 237,131,000 for the six months ended June 30, 2023[127]. Future Outlook - The company aims to enhance its capital efficiency and market competitiveness through strategic allocation of IPO proceeds[98]. - The company anticipates using the remaining unutilized proceeds based on current and future market conditions and business needs[107]. - The company plans to invest approximately RMB 2,244.7 million in the Kangsino Innovative Vaccine Industrial Park project, with funding sources including unutilized proceeds from the A-share IPO[104].

证券代码：688185 证券简称：康希诺 公告编号：2023-044 截至目前，暂无国内疫苗厂商研发的组分百白破疫苗获批上市，公司的婴幼 儿用 DTcP 定位即为进口替代。同时，该款疫苗的开发，也是青少年及成人用组 分百白破疫苗和组分百白破联合疫苗进一步研发的基础。组分百白破疫苗产品组 合将进一步丰富公司产品策略，提升公司核心竞争力。 二、临床试验相关情况 婴幼儿用 DTcP 开展的 I 期临床试验结果显示：该疫苗安全性良好，无 3 级 不良反应的发生，无与疫苗相关的严重不良事件（SAE）的发生。 III 期临床试验将基于 I 期临床获得的研究数据，评价该疫苗在 2 月龄、3 月 龄婴幼儿人群中接种的安全性及免疫原性，进行随机、盲法、阳性疫苗对照的临 床试验。 康希诺生物股份公司 自愿披露关于婴幼儿用吸附无细胞百（组分）白破联合疫苗 启动III期临床试验并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）的婴幼儿用吸附无细胞百（组分） 白破联合疫苗（以下简称"婴 ...

Financial Performance - Operating revenue fell by 79.86% due to a significant decrease in demand for COVID-19 vaccines compared to last year[14] - Net profit attributable to shareholders decreased by 214.94%, leading to a loss for the company[14] - Basic and diluted earnings per share were both -0.57 RMB, compared to 0.49 RMB in the previous year[22] - The company reported a net loss of -170,199, compared to a profit of 114,295 in the same period last year, marking a significant shift in performance[33] - Total operating revenue for Q1 2023 was CNY 100,553 thousand, a decrease of 79.86% compared to CNY 499,355 thousand in Q1 2022[55] - Net profit attributable to shareholders for Q1 2023 was CNY -139,547 thousand, representing a decline of 214.94% year-over-year[60] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.57, a decrease of 216.33% compared to the previous year[60] Assets and Liabilities - Total assets decreased by 2.21% to RMB 11,215,389,000 compared to the previous year[13] - The total non-current assets increased to RMB 3,894,808,000, up from RMB 3,738,775,000[7] - The total assets amounted to 7,320,581, a decrease from 7,730,185, indicating a 5.3% decline[30] - The total liabilities as of Q1 2023 were CNY 4,137,354 thousand, a slight decrease from CNY 4,223,358 thousand in the previous year[54] - The company's total equity decreased to CNY 7,078,035 thousand from CNY 7,245,602 thousand year-over-year[54] - The total equity attributable to shareholders decreased by 2.03% to RMB 6,611,175,000[13] Cash Flow - The company reported a net cash flow from operating activities that was not applicable due to a decrease in cash paid for raw material procurement[14] - The net cash flow from operating activities was -345,404, a decrease from -598,148 in the previous year, indicating a 42.3% improvement[24] - Cash inflow from operating activities totaled CNY 140,298 thousand, compared to CNY 230,369 thousand in the same period last year[49] - Cash and cash equivalents at the end of the period stood at 2,843,894, down from 3,973,871, reflecting a 28.5% decrease[25] - Cash inflow from financing activities was 409,925, down from 517,416, reflecting a 20.8% decrease[24] Research and Development - R&D investment totaled RMB 150,871,000, representing an increase of 118.12 percentage points in R&D expenditure as a percentage of operating income[12] - Research and development expenses accounted for 118.12 percentage points increase in proportion to operating income, due to a larger decline in operating income compared to R&D expenses[49] Shareholder Information - The number of common shareholders at the end of the reporting period was 23,808[4] - The company has a total of 98,066,497 shares held by HKSCC NOMINEES LIMITED, accounting for 39.63% of total shares[4] - The accumulated undistributed profits reached -215,229,160.88, with total share capital at 247,449,899, indicating that the undistributed losses exceed one-third of the paid-in capital[29] Investment Activities - Total cash inflow from investing activities was 2,787,236, up from 2,135,294, representing a 30.6% increase[24] - The net cash flow from investing activities was -172,009, an improvement from -894,010, showing a 80.7% reduction in losses[24] Foreign Exchange - The company experienced a foreign exchange loss of -19,486, compared to -12,150 in the previous year, indicating increased volatility in currency impacts[24] Future Plans - The company plans to issue Global Depository Receipts (GDR) to enhance international financing channels and brand image[28]

Financial Performance - For the first quarter ended March 31, 2023, the company reported a revenue of RMB 100,553,000, representing a decrease of 79.86% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 139,547,000, reflecting a decline of 214.94% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 179,076,000, down 317.82% from the previous year[4] - The basic and diluted earnings per share were both RMB (0.57), a decrease of 216.33% compared to the same period last year[4] - Total revenue for Q1 2023 was RMB 100,553 thousand, a decrease of 79.9% compared to RMB 499,355 thousand in Q1 2022[16] - Net profit for Q1 2023 was a loss of RMB 170,199 thousand, compared to a profit of RMB 114,295 thousand in Q1 2022, indicating a significant decline[17] - Basic earnings per share for Q1 2023 were RMB (0.57), compared to RMB 0.49 in Q1 2022, indicating a significant decline in profitability[18] - The total comprehensive income for Q1 2023 was a loss of RMB (170,166) thousand, compared to a profit of RMB 114,295 thousand in Q1 2022, showing a significant downturn[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 11,215,389,000, a decrease of 2.21% from the end of the previous year[5] - The company's current liabilities decreased to RMB 2,620,183,000 from RMB 2,924,708,000 as of December 31, 2022, indicating improved liquidity[14] - The total liabilities as of March 31, 2023, were RMB 4,137,354 thousand, a decrease from RMB 4,223,358 thousand as of December 31, 2022, reflecting a reduction of 2.0%[15] - The total equity as of March 31, 2023, was RMB 7,078,035 thousand, down from RMB 7,245,602 thousand as of December 31, 2022, a decrease of 2.3%[15] Research and Development - Research and development expenses totaled RMB 150,871,000, representing a decrease of 5.36% year-over-year[4] - The proportion of R&D expenses to operating income was 150.04%, indicating an increase of 118.12 percentage points compared to the previous year[4] - Research and development expenses for Q1 2023 were RMB 149,765 thousand, slightly down from RMB 157,155 thousand in Q1 2022, a decrease of 4.4%[16] Cash Flow and Investments - In Q1 2023, the net cash flow from operating activities was (CNY 345,404,000), a significant improvement from (CNY 598,148,000) in Q1 2022, indicating a reduction in cash outflow[20] - Total cash inflow from investment activities in Q1 2023 was CNY 2,787,236,000, compared to CNY 2,135,294,000 in Q1 2022, reflecting a year-over-year increase of approximately 30.6%[21] - The net cash flow from investment activities was (CNY 172,009,000) in Q1 2023, an improvement from (CNY 894,010,000) in Q1 2022, showing a reduced cash outflow[21] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 2,843,894,000, down from CNY 3,973,871,000 at the end of Q1 2022, representing a decrease of approximately 28.5%[23] - The cash outflow from operating activities totaled CNY 485,702,000 in Q1 2023, down from CNY 828,517,000 in Q1 2022, indicating improved operational efficiency[20] Inventory and Shareholder Information - The total inventory increased to RMB 788,349,000 from RMB 677,777,000, reflecting a 16.3% rise, which may indicate increased production or anticipated sales[12] - The company had a total of 23,808 common shareholders at the end of the reporting period[7] Strategic Initiatives - The company plans to issue Global Depository Receipts (GDRs) and list them on the Swiss Stock Exchange to enhance international financing channels[10] - The company is actively pursuing an internationalization strategy to enhance its brand and image[10] Other Financial Metrics - Other income for Q1 2023 was RMB 33,379 thousand, an increase of 50.0% from RMB 22,297 thousand in Q1 2022[17] - The company reported a credit impairment loss of RMB (11,181) thousand in Q1 2023, compared to RMB (3,143) thousand in Q1 2022, indicating a worsening situation[17] - The impact of exchange rate changes on cash and cash equivalents was (CNY 19,486,000) in Q1 2023, compared to (CNY 12,150,000) in Q1 2022, indicating increased volatility[23] - The total cash inflow from other investment activities was CNY 69,583,000 in Q1 2023, with no comparable figure reported for Q1 2022[21] - The company did not report any cash inflow from financing activities in Q1 2023, indicating a focus on internal funding sources[21]

Financial Performance - In 2022, the company reported a revenue of RMB 1,031,041 thousand, a significant decrease of 76.0% compared to RMB 4,299,702 thousand in 2021[21]. - The operating loss for 2022 was RMB (1,368,742) thousand, compared to an operating profit of RMB 1,911,612 thousand in 2021[21]. - The net loss for the year was RMB (964,757) thousand, a decline from a profit of RMB 1,907,086 thousand in the previous year[21]. - The total equity as of December 31, 2022, was RMB 7,245,602 thousand, down from RMB 8,547,884 thousand in 2021[21]. - Total revenue for the year ended December 31, 2022, was approximately RMB 1,031.0 million, a decrease of 76.0% from RMB 4,299.7 million in 2021[45]. - Gross loss for the year ended December 31, 2022, was approximately RMB 186.6 million, compared to a gross profit of RMB 3,001.9 million in 2021[47]. - Other income increased by 158.3% to approximately RMB 156.9 million for the year ended December 31, 2022, from RMB 60.8 million in 2021[48]. - Sales expenses rose to approximately RMB 266.6 million for the year ended December 31, 2022, from RMB 105.8 million in 2021[49]. - Administrative expenses increased by 20.0% to approximately RMB 278.1 million for the year ended December 31, 2022, from RMB 231.8 million in 2021[50]. - Research and development expenses decreased by 11.4% to approximately RMB 778.3 million for the year ended December 31, 2022, from RMB 878.7 million in 2021[51]. - Financial income increased significantly to approximately RMB 184.7 million for the year ended December 31, 2022, from RMB 25.2 million in 2021, mainly due to foreign exchange gains[53]. - The company's inventory decreased significantly to approximately RMB 677.8 million as of December 31, 2022, from RMB 875.6 million as of December 31, 2021, primarily due to inventory write-downs[57]. - Accounts receivable increased significantly to approximately RMB 855.5 million as of December 31, 2022, from RMB 157.9 million as of December 31, 2021[58]. - The company's intangible assets increased to approximately RMB 162.6 million as of December 31, 2022, from RMB 99.8 million as of December 31, 2021, mainly due to the increase in non-patented technology assets[56]. - Accounts payable decreased significantly from approximately RMB 842.6 million as of December 31, 2021, to approximately RMB 253.1 million as of December 31, 2022, reflecting a reduction in purchase volume[60]. - Other payables and accrued expenses increased by 15.7% from approximately RMB 684.5 million as of December 31, 2021, to approximately RMB 791.9 million as of December 31, 2022, primarily due to an increase in marketing service fees and other payables to suppliers[62]. - Cash and cash equivalents decreased by 37.8% from approximately RMB 5,456.9 million as of December 31, 2021, to approximately RMB 3,394.8 million as of December 31, 2022, mainly due to reduced cash inflow from sales revenue[63]. - Current assets were approximately RMB 7,730.2 million as of December 31, 2022, down from RMB 9,289.8 million as of December 31, 2021[63]. - The company has no significant contingent liabilities that could adversely affect its business or financial condition as of December 31, 2022[66]. - The company is in a net cash position as of December 31, 2022, making the debt-to-equity ratio not applicable[70]. - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[78]. - The company’s revenue growth and strategic initiatives are supported by a strong management team with diverse backgrounds in finance, business development, and regulatory compliance[84]. - The company’s financial reports for the year ending December 31, 2022, were presented alongside the board report, indicating a commitment to transparency in financial performance[127]. - The company did not recommend a final dividend for the reporting period, compared to RMB 197.7 million in 2021[129]. Vaccine Development and Innovation - The company launched the world's first inhalable COVID-19 vaccine, Convidecia Air, in October 2022, which received significant media attention[22]. - The company is developing new vaccines, including a bivalent recombinant COVID-19 vaccine and an mRNA vaccine, with promising safety and immunogenicity profiles[22]. - Convidecia has been widely administered in many countries, contributing to global public health efforts[22]. - The company is collaborating with local partners in Malaysia and Indonesia for vaccine formulation, production, and distribution[22]. - The inhaled recombinant COVID-19 vaccine, Kweisha® Mist, is the world's first aerosolized vaccine that provides triple protection without the need for injections[28]. - Kweisha® received emergency use authorization in multiple countries, including Mexico, Pakistan, and Hungary, and was included in the WHO's emergency use listing in September 2022[28]. - The company is actively collaborating with international partners to establish local production facilities and subsidiaries to enhance global coordination[23]. - The pipeline includes several vaccines in various stages of clinical trials, such as the CS-2023 meningococcal vaccine and the CS-2028 polyvalent pneumococcal conjugate vaccine[26][27]. - The company is focused on developing high-quality vaccines to meet the unmet medical needs in the global market[25]. - Kweisha® and Kweisha® Mist are recommended as second booster vaccines in China as of December 2022[28]. - The company has established a comprehensive marketing and supply system in China since the launch of multiple vaccine products in 2022[23]. - The company’s proprietary adenovirus vector vaccine, Kweisha®, is the first of its kind to enter clinical stages globally, with positive results published in The Lancet for Phase I, II, and III trials[29]. - A Phase IV trial published in Nature Medicine showed that Kweisha® as a booster after an inactivated COVID-19 vaccine demonstrated better efficacy compared to homologous boosters, establishing a strong foundation for emergency use approvals worldwide[29]. - Kweisha® Mist, a novel delivery method, has shown to induce triple immune protection with a dosage only 1/5 of the intramuscular Kweisha®, enhancing its appeal due to its pain-free and convenient administration[29]. - The company announced ongoing clinical studies for Kweisha® and Kweisha® Mist in various age groups, with positive interim data supporting the upgrade of immunization strategies[29]. - The company’s meningococcal vaccine, Manhaixin®, received approval in December 2021, becoming China’s first MCV4 vaccine, filling a significant gap in high-end vaccines in the country[31]. - Manhaixin® has been commercialized and penetrated nearly 30 provinces in China, with a growing market presence[31]. - The company’s Ad5-EBOV vaccine, approved for emergency use in 2017, is recognized for its stability and safety, although it is not expected to make significant commercial contributions in the near term[32]. - The mRNA COVID-19 vaccine CS-2034 has shown promising interim data, with a geometric mean titer (GMT) of 407 against the Omicron BA.5 variant, which is 29 times higher than that of inactivated vaccines[33]. - The company has initiated Phase Ib clinical trials for its innovative non-serotype pneumococcal vaccine, PBPV, which aims to provide broader protection than existing serotype vaccines[35]. - The company plans to begin the new drug registration application process for the improved PCV13i vaccine in 2023 following the completion of Phase III trials[34]. - The company is developing a DTcP vaccine for infants in China, which contains three types of pertussis antigens, providing better protection compared to the existing vaccine with two antigens[36]. - The Phase I clinical trial for the DTcP vaccine was completed in 2020, but development has been delayed due to resource allocation to Ad5-nCoV, with Phase III trials expected to start in 2023[36]. - The company is also working on a DTcP booster vaccine for children aged 4 to 6, with no approved vaccines currently available in China for this age group, indicating unmet demand[37]. - The company has initiated communication with the National Medical Products Administration for clinical trial applications for the adolescent and adult Tdcp vaccine, which is expected to progress further[38]. - A novel tuberculosis booster vaccine is under development, showing good safety and tolerance in Phase I trials, with plans for further clinical trial evaluations[39]. - The company is establishing an mRNA technology platform in Shanghai, aiming to develop innovative preventive vaccines with significant advantages over traditional platforms[41]. - The company has established a vaccine production base with an annual capacity of nearly 100 million doses, designed and operated in compliance with national and international GMP standards[71]. - The company has been involved in various international clinical trials for its COVID-19 vaccine, with successful approvals in countries like Pakistan, Mexico, Russia, and Chile[83]. - The company has made significant investments in research and development, focusing on new vaccine technologies and expanding its product pipeline[83]. Corporate Governance and Management - The board consists of five executive directors, three non-executive directors, and four independent non-executive directors[88]. - The company has adopted all applicable provisions of the corporate governance code as per the Hong Kong Listing Rules Appendix 14[86]. - The company confirms that all directors and supervisors complied with the standard code during the reporting period[87]. - The board believes that the current structure of having the chairman also serve as the CEO is beneficial for the company's business prospects and operational efficiency[90]. - The company has a set of director nomination policies that consider individual character, professional qualifications, skills, knowledge, and experience relevant to the group's business and strategy[92]. - The board is responsible for leading and monitoring the company, guiding and supervising its affairs, and ensuring good internal control and risk management systems[93]. - The company has received written annual confirmations of independence from all independent non-executive directors[91]. - The company will continue to review the effectiveness of its corporate governance structure to assess whether the roles of chairman and CEO should be separated[90]. - The independent non-executive directors account for one-third of the board, with at least one possessing appropriate professional qualifications or financial management expertise[91]. - The company has established written guidelines for employees regarding securities trading to prevent insider trading[87]. - The company has established three committees: Audit Committee, Remuneration and Nomination Committee, with specific written terms of reference for each[96]. - The Audit Committee held five meetings during the reporting period and reviewed the financial reporting procedures and internal control systems[97]. - The Remuneration and Nomination Committee reviewed the remuneration policies for directors and senior management, ensuring compliance with applicable regulations[98]. - The senior management's salary range for the year ended December 31, 2022, included one individual earning between HKD 2,000,001 and HKD 2,500,000, one earning between HKD 3,000,001 and HKD 5,000,000, and one earning between HKD 5,000,001 and HKD 6,000,000[99]. - The company provides liability insurance for directors and senior management against legal actions arising from company affairs[95]. - Continuous professional development is encouraged for all directors to ensure they remain informed about their responsibilities and relevant regulations[95]. - The Audit Committee reviewed related party transactions to ensure compliance with legal and regulatory requirements[97]. - The company has a policy for director remuneration that includes annual director fees and potential stock options or awards[100]. - The company ensures that all directors receive comprehensive onboarding to understand the business and operations effectively[95]. - The company conducts regular training sessions for directors on relevant laws and regulations to keep them updated[95]. - The board consists of 12 members, including 5 executive directors, 3 non-executive directors, and 4 independent non-executive directors, with a gender ratio of 3 female to 9 male directors[102]. - Employee gender distribution shows 53.78% male and 46.22% female, indicating a balanced gender diversity within the company[103]. - The company has established a nomination committee to evaluate the independence of independent non-executive directors and review the board's structure and diversity policies[101]. - The board's independence exceeds the Hong Kong Stock Exchange's requirements, with 4 out of 12 directors being independent non-executive directors[104]. - The company has implemented a whistleblowing policy to encourage reporting of misconduct, ensuring confidentiality and protection for whistleblowers[106]. - The company has developed compliance manuals and anti-corruption policies to enhance daily oversight capabilities against bribery and corruption[105]. - The board aims to maintain the current female representation and ultimately achieve gender equality[102]. - The nomination committee will review the board diversity policy annually and set measurable targets for achieving diversity[102]. - The board held eight meetings during the reporting period, ensuring active participation from directors[109]. - The company is committed to regular reviews of its anti-corruption policies and whistleblowing mechanisms to ensure effectiveness[106]. - The board emphasizes that corporate culture is the foundation for long-term business development and economic achievement[111]. - The company has appointed experienced professionals in key management positions to enhance its operational efficiency and strategic direction[84]. Risk Management and Compliance - The board is responsible for evaluating and determining the nature and extent of risks the company is willing to take to achieve strategic objectives, maintaining effective risk management and internal control systems[113]. - The company has implemented various risk management procedures and guidelines to identify risks affecting its business, including operational, financial, regulatory compliance, and data security risks[113]. - The board confirms that there are no significant uncertainties that may severely affect the company's ability to continue as a going concern[114]. - The company has maintained compliance with all relevant laws and regulations during the reporting period, with no significant violations reported[181]. - Related party transactions were conducted fairly and in accordance with legal regulations, with no actions found that harmed the company's or shareholders' interests[194]. - The independent auditor's report confirms that the consolidated financial statements fairly present the financial position and performance of the group as of December 31, 2022, in accordance with Hong Kong Financial Reporting Standards[197]. Shareholder Relations and Communication - The company encourages shareholders to participate in general meetings and has established procedures for calling extraordinary general meetings upon request from shareholders holding more than 10% of shares[117]. - The company has strengthened its cultural framework during the reporting period, focusing on respect, agility, innovation, quality first, and dedication as core values[111]. - The company has established multiple communication channels with shareholders, including annual and extraordinary general meetings, to enhance investor relations and transparency[122]. - All resolutions presented at the annual general meeting on June 29, 2022, and the extraordinary general meeting on December 21, 2022, were approved[122]. - The company allows shareholders holding more than 3% of shares to propose temporary motions 10 working days before the general meeting[118]. - The company’s articles of association were amended and approved by shareholders on June 29, 2022, with no significant changes since December 31, 2022[123]. - The company emphasizes timely and unfiltered disclosure of information to enable informed investment decisions by shareholders[121]. - The company’s communication policy is regularly reviewed to ensure effectiveness in addressing shareholder concerns[124]. Future Plans and Investments - The company plans to invest approximately RMB 2,244.7 million in the innovative vaccine industrial park project to enhance manufacturing capacity[65]. - The company plans to issue Global Depositary Receipts (GDR) and list them on the Swiss Stock Exchange to enhance international financing channels and brand image[129]. - The company is currently evaluating the issuance scale and fundraising purposes for the proposed GDR issuance[129]. - The company anticipates that the remaining balance of the A-share IPO proceeds will be fully utilized by the end of 2024[170]. - The company has allocated RMB 112.2 million for working capital and other general corporate purposes, reflecting a rise from RMB 5.5 million[166]. - The expected timeline for utilizing the remaining balance of the A-share IPO proceeds is by the end of 2024[168]. - The company has experienced delays in the progress of other major products due to resource allocation towards the Ad5-nCoV project[166]. - The company aims to enhance its vaccine product portfolio to improve market competitiveness[164].

重要内容提示： （网址：http://roadshow.sseinfo.com） 说明会议召开方式：视频和网络文字互动 投资者可于 2023 年 4 月 25 日（星期二）16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱 ir@cansinotech.com 进行提问。公司将 在说明会上对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）于 2023 年 3 月 28 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年年度经营成果、 财务状况，公司参与了由上海证券交易所主办的 2022 年度生物制品专场集体业 绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海 证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 证券代码：688185 证券简称：康希诺 公告编号：2023-022 康希诺生物股份公司 关于参加 2022 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其 ...

Financial Performance - The company reported a net loss for the year 2022, continuing its trend of unprofitability since its IPO[2]. - The company reported a revenue of 1.5 billion in 2022, representing a year-over-year growth of 20%[166]. - The company provided a forward guidance of 1.8 billion in revenue for 2023, expecting a growth rate of 20%[166]. - The company’s net profit attributable to shareholders turned to a loss due to a substantial decline in COVID-19 vaccine sales revenue compared to the same period last year[86]. - The company reported a net cash flow from operating activities of -1,851,545 thousand RMB, a decrease of 190.32% compared to the previous year[67]. - The company’s cash and cash equivalents decreased by 38.62% to 3,464,734 thousand RMB compared to the previous year[71]. - The company’s investment activities resulted in a net cash flow of -1,227,641 thousand RMB, a decrease of 52.05% from the previous year[67]. - The company reported a significant increase in short-term borrowings, rising by 54.42% to 1,529.8 million[85]. - The company’s long-term borrowings increased dramatically by 2,095.02% to 878.0 million, primarily due to new loans for special projects and working capital[85]. - The company’s total sales revenue from major customers reached 520,329 thousand RMB, accounting for 40.49% of total annual sales[64]. Research and Development - The company is focused on the research and development of vaccines and related biotechnologies, aiming to expand its product offerings[34]. - The company has developed a universal mRNA technology that significantly shortens product development time and facilitates rapid industrialization[46]. - The company has established various carrier protein production technologies and coupling techniques for polysaccharide vaccines, enhancing the quality of its multivalent and combination vaccines[45]. - The R&D pipeline includes vaccines for COVID-19, meningitis, Ebola, diphtheria, pertussis, tuberculosis, and shingles, addressing urgent clinical needs[152]. - R&D investment for the mRNA COVID-19 vaccine amounted to CNY 130,415,000, representing 12.61% of total revenue, with a year-over-year increase of 119.11%[114]. - The company has improved existing vaccine products through gene engineering and protein engineering, significantly enhancing antigen yield and simplifying production processes[128]. - The company has developed an inhaled recombinant novel coronavirus vaccine (5-type adenovirus vector) for COVID-19 prevention[92]. - The company has developed a recombinant COVID-19 vaccine (Ad5 vector) and is progressing on a tuberculosis booster vaccine (Ad5Ag85A), leveraging its adenovirus vector technology platform[128]. - The company completed Phase IIb clinical trials for its mRNA COVID-19 vaccine and Phase III clinical trials for the PCV13 vaccine[96]. - The PCV13 vaccine development costs were partially capitalized, with CNY 11,625,000 recognized as capitalized expenses[114]. - The DTcP vaccine's R&D investment was CNY 19,337,000, accounting for 1.87% of total revenue, with a year-over-year increase of 42.12%[114]. - The TB vaccine has completed Phase Ib clinical trials, indicating progress in its development[96]. Market and Strategic Developments - The company plans to invest hundreds of millions in vaccine development, facing risks of potential failures in final development[39]. - The company is actively expanding its marketing network and enhancing its cold chain logistics to improve product penetration[117]. - The company is focusing on importing high-quality vaccines to replace existing products in developed markets, with MCV4 being the first approved product in China using the CRM197 carrier protein[140]. - The company plans to enhance its customer engagement through improved digital platforms, aiming for a 25% increase in customer satisfaction scores[166]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 200 million allocated for potential deals[166]. - The company is involved in various related party transactions as per the annual report[182]. - The company has established agreements to ensure compliance with shareholder obligations, reflecting a commitment to governance[160]. - The company is committed to operational management and strategic development, as highlighted by the roles of its executive team[161]. - The company aims to deepen its R&D platform management and explore global cooperation opportunities to enhance long-term operational and profitability capabilities[142]. - The company is actively engaging in corporate governance improvements, including revisions to internal management systems[177]. Governance and Management - The audit report issued by Deloitte Huayong confirmed the financial statements with a standard unqualified opinion[7]. - The company has established specialized committees, including an audit committee, nomination committee, and compensation and assessment committee, to enhance governance[189]. - The company has a strong leadership team with extensive experience in the biotechnology and pharmaceutical industries[161]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period was 37,487[197]. - The total remuneration for core technical personnel at the end of the reporting period was 24,374[197]. - The company has not reported any changes in shareholding for its non-executive directors during the reporting period[158]. - The company has not faced any penalties from securities regulatory agencies in the past three years[176]. - The company has implemented a plan for share repurchase through centralized bidding, reflecting its commitment to shareholder value[198]. - The company has not identified any risks during the supervisory review conducted by the supervisory board[191]. - The company has a diverse workforce, with 32 employees holding doctoral degrees and 416 holding master's degrees[193]. Operational Challenges and Risks - The company highlighted significant risk factors that could adversely affect its operations, urging investors to be cautious[12]. - The company has not encountered any non-operational fund occupation by controlling shareholders or related parties[29]. - The company’s inventory of COVID-19 vaccines was subject to impairment provisions due to market conditions, leading to increased sales expenses[86]. - The management discussed future plans and strategic developments, emphasizing the importance of risk awareness in investment decisions[8]. - The company has established a drug safety monitoring system to ensure public medication safety[78]. - The company has not disclosed any plans for profit distribution or capital increase through reserves during the reporting period[13]. Charitable Activities - The company made charitable donations totaling 1.18 million, including 1.13 million to foundations and 0.136 million for rural revitalization and pandemic support activities[91].